Oscotec R&D Day

November 24, 2025

Translating Science into Medicine

Oscotec Inc.

Disclaimer

- This presentation has been prepared by Oscotec Inc.(the “Company”) solely for its own use at its presentation to company investors.

- Information contained herein is strictly confidential, and is given only for your information and for your use and may not be copied, reproduced, distributed, redistributed or passed on, directly or indirectly, to any other person in any manner, or published, in whole or in part, for any purpose. Certain statements contained herein constitute forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. Words such as “anticipates,” “plans,” “estimates,” “expects” and variations of these words and similar expressions are intended to identify forward-looking statements. Such statements address future financial results and business standings.

- **Forward-looking statements** are not guarantees of future performance and involve certain uncertainties and risks, which are affected by further changes in business environment. Therefore, actual future results and trends may differ materially from the forecasts reflected in the forward-looking statements herein due to a variety of factors including but not limited to the changes in market conditions and strategy revisions.

- The Company is not liable for any investment decisions by its readers or subscribers and does not undertake any legal obligation to present any supporting evidence against investment results of investors under any circumstances.

R&D Pipeline 2025

	MoA	Indication	Discovery	Lead Opt	Preclinical	Phase I	Phase II	Partner
Cevidoplenib (SKI-O-703)	SYK Inhibitor	RA						
		ITP						
Denfivontinib (SKI-G-801)	FLT3/AXL Dual Inhibitor	AML						
		Solid tumors						
ADEL-Y01	Anti-TAU mAb	Alzheimer						ADEL We dream of a world without dementia.
OCT-598	EP2/4	Cancer						KANAPH Therapeutics Inc.
OCT-648	NUAK1	Fibrosis						
ONC1	NUAK1/2	Cancer						
ONC2	(Undisclosed)	Cancer						
ONC3	(Undisclosed)	Cancer						

Cevidoplenib

- History
  - One of the most advanced SYK-selective inhibitors worldwide (solvleplenib, BI-894416)
  - Proven competitive efficacy and superior tolerability in chronic ITP patients (2nd line) in global P2 study
- Current status
  - Initiated an investigator-initiated P2 study in newly diagnosed ITP patients (1st line)
  - Developed new crystal forms and formulation; patent application filed
  - High quality drug products manufactured; bioequivalence study planned
- Prospect
  - To explore new indications to maximize the potential value via partnering and external investment

FIERCE Biotech | Biotech | Research | Medtech | CRO | Special Reports | Trending | Fierce 50 | Awards

BIOTECH

Sanofi signs €545M deal to explore Formation's JAK/SYK inhibitor in new indication

By James Waldron · Jun 23, 2025 9:47am

FIERCE Biotech | Biotech | Research | Medtech | CRO | Special Reports | Trending | Fierce 50 | Awards

BIOTECH

Ignota buys Kronos' pipeline, igniting 2nd chance salvo to rescue shelved programs

By Nick Paul Taylor · Oct 6, 2025 5:45am

Article | Open access | Published: 17 February 2025

Syk inhibitor attenuates lupus in FcγRIIb$^{-/-}$ mice through the Inhibition of DNA extracellular traps from macrophages and neutrophils via p38MAPK-dependent pathway

Kritsanawan Sae-khow, Awirut Charoensappakit, Kanyarat Udompornpitak, Wilasinee Saisorn, Jiraphorn Issara-Amphorn, Tanapat Palaga & Asada Leelahavanichkul

Cell Death Discovery **11**, Article number: 63 (2025) | Cite this article

* ITP = immune thrombocytopenia

Denfivontinib

- History
  - A potent FLT3/AXL dual inhibitor
  - Completed P1a as an injectable in AML patients in the US; confirmed efficacy in the subjects with FLT3-mutation
  - Strategic decision to halt further development in AML due to the lack of differentiation vs Xospata® (gilteritinib, Astellas)
  - Completed P1a as an oral pill in solid tumors in Korea; confirmed good exposure (PK) and safety
  - Strategic decision to deprioritize as OCT-598 advances
- Prospect
  - Potential collaboration/option deal on developing companion diagnostics for AML



Carter et al., Signal Transduction and Targeted Therapy, 2020

* AML = acute myeloid leukemia; PK = pharmacokinetics

ADEL-Y01

- History
  - Acetyl K280-tau-targeting monoclonal antibody for Alzeheimer's disease
  - Joint development agreement with Adel, Inc. in 2020
  - Initiated P1 study in the US in 2023
- Current Status
  - Completed P1a single-ascending dose part in healthy volunteers; data to be presented in CTAD 2025
  - P1b multiple-ascending dose part in early AD patients underway
  - Protocol amendment to include prescreening (pTau 217) and dosing adjustment (q4w)
- Prospect
  - Potential licensing agreement with a global pharma before P2



Fitzpatrick et al., Nature 2017



* CTAD = Clinical Trials in Alzheimer's Disease;AD = Alzheimer's disease

OCT-598

- History
  - An EP2/4 dual antagonist, anticipated to help overcome cancer therapy resistance and immune evasion
  - In-licensed from Kanaph Therapeutics in 2022
  - Preclinical data presented at AACR 2023 and 2025
- Current Status
  - IND approved by FDA (June) and MFDS (November)
  - First-in-human dosing to start in December
- Prospect
  - P1b docetaxel combination to start in mid-2026 in multiple solid tumor types; a second combination regimen planned to start in-late 2026 (CRC or SCLC)
  - Trailblazing the development path for CTR programs to follow

FIERCE Biotech
Biotech Research Medtech CRO Special Reports Trending Fierce 50

BIOTECH

Ono's BMS-partnered EP4 antagonist improves progression-free survival in phase 2 gastric cancer test

By James Waldron · Oct 9, 2025 10:10am



* CRC = colorectal cancer; SCLC = small cell lung cancer; CTR = Caner Therapy Resistance

Coming Soon; OCT-648 for Kidney Fibrosis

- **What it is**
  - Highly selective NUAK1 inhibitor
  - Hypothesis; NUAK1/2-mediated YAP-activation drives injury-induced fibrosis
  - CTR target biology translated into fibrosis
- Current Status
  - PoC obtained in animal CKD models (UUO)
  - Preclinical data to be presented at WCN 2026
  - Backup program to increase odds of success
  - Targeting CKD (or AKI-to-CKD)
- Prospect
  - Enter preclinical development in 2026
  - Early L/O potential along with GCN-3545 in P1



Habshi, Drug Disc Today 2023



Skalka et al., Essays Biochem 2024

* CTR = Cancer Therapy Resistance; PoC = Proof-of-Concept; CKD = chronic kidney disease; UUO = unilateral ureteral obstruction; WCN = World Congress of Nephrology; AKI = acute kidney injury; L/O = license out

In the Pipeline; Cancer Therapy Resistance *What's Next after Lazertinib?*









- ***ONC1 (Nuak1/2)***
  - *Proof of concept w/ P4899 (AACR 2025)*
  - *Candidate selection by 4Q 2026*
- ***ONC2 & ONC3 (undisclosed)***
  - *Hit-to-lead stage*
  - *Candidate selection in 2027/2028*
- ***CTR Platform for accelerated target/hit finding***

R&D Roadmap 2020-2030



- +2 Preclinical candidates
- Double the R&D capability
- Cancer therapy resistance platform
- Map out the expansion plan
  - New modality/technology
  - New disease area

- +2 Preclinical candidates
- Continued focus on CTR
- Partnership (Collabo, L/I, or M&A) for expansion

Oscotec Inc.

Vision 2030

- The inventor, pioneer, and champion of **"anti-cancer-anti-resistance therapy"**
- The number one '**first-in-class'** drug discovery company in Korea
- Global reputation for;
  - Innovative pipeline
  - Breakthrough clinical results
  - **Multiple high-profile partnership deals**

경영 현안 및 향후 계획

1 제노스코 완전 자회사화

– 지배구조 및 운영의 효율성 제고

– 가치평가와 의사결정 전 과정에서의 투명성 및 공정성 확보

2 자본 배분 (Capital Allocation) 계획

– 재정적 자립 달성 및 자본의 효율적 배분

3 중장기 로드맵 및 주주가치 제고 계획 마련

– 단기 수익성과 중장기 혁신 병행으로 지속가능한 안정적 성장 기반 구축

Oscotec Inc.

History to Repeat Itself



Phase 1
Start up

Phase 2
Grow up

Phase 3
Scale up

Oscotec Inc.

Translating Science into Medicine